Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors

by Boland, G.M, Cohen, S.
Published 2022

Antihistamines for cancer immunotherapy: More than just treating allergies

by Chen, S., Luster, A.D
Published 2022

A multispecies framework for modeling adaptive immunity and immunotherapy in cancer

by Cao, Y., Qi, T., Vincent, B.G
Published 2023

Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors

by Bell, A.T.F, Bialkowski, L., Çuburu, N., Kim, R., Lowy, D.R, Pontejo, S.M, Schiller, J.T, Sethi, S.K, Thompson, C.D
Published 2022

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

by Chittepu, V.C.S.R, Farrukh, H., Pan, C.-X, Pan, K., Xu, H., Zhu, Z.
Published 2022

Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines

by Broach, V., Cohen, S., Navitski, A., O'Cearbhaill, R.E, Praiss, A., Tessier-Cloutier, B.
Published 2022

A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies

by Akram, A.R, Barth, N.D, Bravo-Blas, A., Carragher, N.O, Cheng, Z., Connor, R.A.O, Dawson, J., de Vries, I.J, Frame, M., Gordon, D., Juarez-Jimenez, J., Kitamura, T., Mendive-Tapia, L., Michel, J., Piet, B., Roberts, E.W, Scott, J.I, Serrels, A., Taggart, D., Thompson, E.J, Vendrell, M., Verdoes, M.
Published 2022

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

by Faleck, D.M, Harris, J.P, Postow, M.A
Published 2022

Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen

by Bellile, E., Bryan Bell, R., Campos, C.Z, Cernea, C.R, Cruz, F.J.S.M, D'Silva, N., Erman, A., Girotto, G.C, Higgins, K., Kaplan, M., Kraus, D., Krempl, G., Liu, S., Martins, W.A, McCaul, J., Moyer, J., Newman, J., Nguyen, A., Nieva, J., Oliveira, F., Panwar, A., Patel, M., Rozek, L., Sartor, M.A, the INSPIRE Trial Clinical Investigators, Valentino, J., Victorina, A.P, Wolf, G.T, Zarins, K.
Published 2021

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

by Aguilar, E., Aguilar, L.K, Barone, F., Chiocca, E.A, Griffith, A.M, Guzik, B.W, Koch, M.S, Lawler, S., Lederer, J.A, Nowicki, M.O, Tabatabai, G., Tak, P.P, Zdioruk, M.
Published 2022

An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

by Belardinilli, F., Giannini, G., Licursi, V., Paci, P., Sibilio, P.
Published 2022

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

by Chan, N., Chan, T., de Meritens, A.B, Ganesan, S., Girda, E., Groisberg, R., Jabbour, S.K, Leiser, A., Malhotra, J., Mayer, T., Mehnert, J., Palmeri, M., Popli, P., Riedlinger, G., Silk, A.W, Spencer, K., Stephenson, R., Subbiah, V.
Published 2022

Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells

by Fan, Q., Huang, C., Kong, Q., Nice, E.C, Shi, Z., Tian, H., Zuo, J.
Published 2022

Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy

by An, R., Chen, S., Chu, Y., Gao, Y., Li, G., Wang, H., Wang, Y., Xie, X., Zhang, J.
Published 2022

Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti–PD-1/PD-L1 immunotherapy in lung adenocarcinoma

by Chen, Y., Li, T., Zhang, X., Zhou, M.
Published 2021

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

by Bian, J., Chen, P., Lin, Y., Long, J., Sang, X., Wang, A., Wang, D., Yang, X., Zhang, H., Zhao, H., Zheng, M., Zheng, Y.
Published 2022

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

by Chen, R., Chen, Y., Jiang, G., Liu, F., Mao, W., Mei, J., Wan, Y., Xu, J., Xu, Y., Zheng, M.
Published 2022

Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study

by Aerts, J.G, Bezemer, K., de Koning, W., de Miranda, N.F.C.C, Doukas, M., Dumas, J., Klaase, L., Lau, S.P, Luider, T.M, Mustafa, D.A.M, Nunes, J.B, Stadhouders, R., Stingl, C., Stubbs, A.P, van der Breggen, R., van der Burg, S.H, van Eijck, C.H.J, van Krimpen, A., Vink, M., Vroman, H., Wismans, L.V
Published 2022

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy

by Jung, K., Kim, C.-H, Kim, J.-A, Kim, Y.-S, Ko, D.-H, Lee, S.-Y, Son, M.-J, Yoo, S.
Published 2022

Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy

by Gao, Z., Gong, J., Jiang, S., Liu, Z., Wang, X., Zhang, M., Zhang, Z.
Published 2022